Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy

Jun 23 2020

• By Malcolm Spicer

Funding Folders

Related Content

Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

Sep 06 2018

Ohio Study Shows Access To Naloxone Soars Without Rx Requirement

Feb 12 2020

FDA's OTC Naloxone Model Labels Confirmed In CONFER Study

Jan 18 2019

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals

Jan 18 2019

Purdue's Support For OTC Naloxone Would Continue In Bankruptcy

Sep 22 2019

Related Companies

Purdue Pharma L.P.

Additional Topics

United States Prescription To OTC Switch Research & Development FDA Drug Approval Standards Clinical Trials Commercial Companies Drug Review Drug Safety Ingredients Manufacturing OTC Drugs Safety Financing Consumer Respiratory Cardiovascular

More from Rx-to-OTC Switch

More from Health

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window